The Canadian Nuclear Safety Commission has approved an expansion of medical isotope production at the Darlington nuclear plant, which is the largest isotope production facility in North America. This expansion will enhance the availability of critical isotopes such as Yttrium-90 (Y-90) and Lutetium-177 (Lu-177), crucial for targeted radionuclide therapies that treat difficult cancers like liver, neuroendocrine, and prostate cancer. The isotopes produced at Darlington, using a unique CANDU reactor design, will allow for continuous electricity generation while supplying medical needs. Expected to increase production to nearly three million doses of Lu-177 yearly, the initiative aims to address the growing demand for cancer treatments and solidify Ontario’s position as a leader in nuclear medicine. The initiative is anticipated to support improved cancer care globally and create skilled jobs in the region.
Wed, 28 May 2025 13:01:31 GMT | INsauga